- Conditions
- HIV Infections
- Interventions
- pGA2/JS7 DNA vaccine, Placebo, MVA/HIV62 vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 68
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
- Interventions
- VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 15 Years to 35 Years
- Enrollment
- 2,428 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Miami, Florida • Edinburg, Texas • Houston, Texas
- Conditions
- HIV Infections
- Interventions
- DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine, Placebo for DNA-HIV-PT123 vaccine, Placebo for NYVAC-HIV-PT1 vaccine, Placebo for NYVAC-HIV-PT4 vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- Placebo, EP-1300
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Herpes Zoster
- Interventions
- HZ Vaccine (IN001), Placebo, Shingrix
- Biological
- Lead sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
- Industry
- Eligibility
- 50 Years to 69 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Hollywood, Florida
- Conditions
- HIV Infections
- Interventions
- PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more
- Conditions
- Covid19
- Interventions
- Heterologous stimuli, Neutralization assay
- Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cytomegalovirus Infection
- Interventions
- mRNA-1647, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 16 Years to 40 Years · Female only
- Enrollment
- 7,454 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 181
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 141 more
- Conditions
- HIV Infections
- Interventions
- HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
- Biological
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
- Conditions
- HIV Infections
- Interventions
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 2,504 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2017
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Meningococcal Immunisation, Healthy Volunteers
- Interventions
- Multicomponent Meningococcal B Vaccine, Meningococcal Group B Vaccine MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed), Placebo, Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
- Drug
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 50 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Guntersville, Alabama • San Diego, California • Tampa, Florida + 5 more
- Conditions
- HIV, Therapeutic Vaccine
- Interventions
- rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- ASC-US, ASC-H, LSIL
- Interventions
- PVX-2, Placebo
- Biological · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 25 Years to 70 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
- Conditions
- HIV Infections
- Interventions
- DNA CON-S env, IHV01, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections
- Interventions
- AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine, Placebo for DNA-HIV-PT123, Placebo for AIDSVAX B/E
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- San Francisco, California • New York, New York • Rochester, New York + 3 more
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- AIC (Amb a 1 Immunostimulatory Conjugate)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cytomegalovirus Infection
- Interventions
- mRNA-1647, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Seattle, Washington
- Conditions
- Allergic Rhinitis
- Interventions
- CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
- Biological · Other
- Lead sponsor
- Immunomic Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
- Interventions
- iSCIB1+, Nivolumab & Ipilimumab, Placebo
- Biological · Drug · Other
- Lead sponsor
- Scancell Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HIV Infection
- Interventions
- PENNVAX-B, GENEVAX IL-12-4532, PLACEBO, IL-15 adjuvant
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Herpes Genitalis
- Interventions
- VCL-HB01, Phosphate-buffered saline
- Biological · Other
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more
- Conditions
- HIV Infections
- Interventions
- HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2008
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee
- Conditions
- Hantavirus Pulmonary Infection, Immunisation
- Interventions
- Andes virus DNA vaccine, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
- Interventions
- PVX4 Combination Product, Placebo Control
- Combination Product · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- The Bronx, New York